Home › Myelodysplastic Syndromes › Minnesota
Myelodysplastic Syndromes clinical trials in Minnesota
13 studies for Myelodysplastic Syndromes are looking for participants at sites in Minnesota.
Cities in Minnesota
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- and 8 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06577441The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Masonic Cancer Center, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT06594445Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 75 · All sexes · Updated Jul 6, 2026 · NCT05805605A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT03017820MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Ages 2 to 75 · All sexes · Updated Apr 16, 2026 · NCT07493538A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Comprehensive Cancer Center, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT05732103Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 65 · All sexes · Updated Jan 30, 2026 · NCT03579875SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 10, 2025 · NCT06712810Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- University of Minnesota, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.